Fix the Patent Laws Coalition supports South Africa and India’s proposal to facilitate access to COVID-19 vaccines 15 October 2020, Johannesburg - The Fix the Patent Laws Coalition (FTPL), a…
SECTION27's submission to the Department of Trade and Industry on the Copyright Amendment Bill 2015 SECTION27’s primary interest in intellectual property policy and law reform flows from its understanding of…
On 9 – 10 November 2012, the Treatment Action Campaign (TAC), SECTION27 and the Medicines Patent Pool (MPP) brought together global treatment activists to discuss guiding principles and access maximising provisions for terms and conditions that should be sought in the licenses negotiated by the MPP and others.
On 26 July 2012, the Supreme Court of Appeal handed down its judgment in the matter between the Aventis group of pharmaceutical companies and Cipla’s group of generic pharmaceutical companies.
This is the first judgment to decisively say that public interest considerations must be taken into account when balancing the interests of the patentee and the infringer in determining whether or not to grant an interim interdict. The judgment is an important advance in the law that is in line with the values of the Constitution.
Cabinet recently resolved to ask Parliament to take the necessary steps to enable South Africa to ratify a decision taken by the World Trade Organization (WTO) on intellectual property and access to medicines. At its meeting held on 16 March 2011, Cabinet decided to request Parliament to –
– ratify the WTO decision on the implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health; and
– deposit “an instrument of ratification … with the WTO.”
As organisations that are committed to ensuring universal access to essential medicines, as an integral part of the constitutional right to have access to health care services, TAC and SECTION27 call on Parliament not to ratify the decision. In this press statement we explain why we make this call.
Letter to the High Commissioner for India to South Africa: Our concerns regarding Indian trade negotiations with EU.
This letter explains that the prospect of making new ARVs available in South Africa at affordable prices is under threat because of events unfolding in India. In particular, pressure is being applied by the European Union on the Indian government to sign a bilateral trade agreement that will stifle competition on essential medicines still under patent.
The AIDS Law Project (ALP) and the Treatment Action Campaign (TAC) welcome this opportunity to make written submissions on the Patents Amendment Bill [B 17 – 2005] (“the Bill”). As two organisations that have consistently advocated for the development of our patent system into one that considers South Africa’s competitive advantage and takes into account the specific needs of its people, we support what the Bill aims to achieve and, in general terms, how it goes about accomplishing its stated objective.
The global AIDS epidemic is one of the greatest threats to security and development in the world. Millions of people in developing countries are dying of AIDS, TB and malaria – while the first world sits idly by. High prices of medicines, protected from competition by patent law, make it impossible for poor people to protect themselves against illness and death.